Skip to main content

Karl Kieburtz, MD, MPH

Professor of Neurology and Community and Preventitive Medicine at University of Rochester Medical Center

Location: Rochester, NY United States

Karl Kieburtz obtained his BA in Neuroscience from Amherst College. He completed his MD and MPH degrees at the University of Rochester, as well as his residency and a fellowship in Experimental Therapeutics. He is currently a Professor in the Departments of Neurology and Community and Preventative Medicine and is the Director of the Clinical Trials Coordination Center (CTCC) at the University of Rochester. In addition, he is the chair of the Parkinson’s Study Group (PSG) Executive Committee and Executive Committee member and Coordination Center Director for the Huntington Study Group (HSG). Both the PSG and HSG, along with the CTCC, foster multi-institutional academic research and coordinate multi-center trials examining the symptomatic and neuroprotective effects of experimental interventions for neurodegenerative diseases. 

Dr. Kieburtz’s research interests focus on treating neurodegenerative diseases, particularly Parkinson’s disease and Huntington’s disease. He is also interested in trials of potential neuroprotective agents for the treatment of neurodegenerative diseases. He has active or prior NIH funding as a principal investigator or co-principal investigator for multi-center trials in PD, HD, and HIV-related neurological disorders. 

Dr. Kieburtz is chair of the FDA Peripheral and Central Nervous System Drugs Advisory Committee and sits on the American Academy of Neurology (AAN) Clinical Research Subcommittee, the International Executive Committee of the Movement Disorders Society (MDS), the Board of Directors for the American Society for Experimental NeuroTherapeutics (ASENT), and the Council of the American Neurological Association (ANA).

Associated Grants

  • Making PSG Databases Available to Researchers


  • NIC-PD Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease


  • Ethics of Sham Surgery Controls to Test Novel Parkinson's Disease Interventions


  • Inosine for Parkinson's Disease: Safety and Trial Design Optimization


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.